Saturday 17 October 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 42.9%, EPS fell 2,827.3%, free cash flow fell 399.4% and total debt rose 201.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.04
0.15
−4.70%
Follow MNKD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
52.54 | 255.41 | 0.00 | 0.00 |
P/S ratio |
5.25 | 4.97 | 2.09 | 3.35 | |
P/FCF ratio |
37.97 | 126.60 | 57.43 | 0.00 | |
P/Operating CF |
69.69 | (217.76) | (140.77) | (71.70) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.10 | 5.79 | 2.89 | 4.14 | |
EV/EBITDA |
19.34 | 38.89 | 32.02 | 51.74 | |
EV/Operating CF |
32.76 | 110.64 | 54.15 | (202.15) | |
EV/FCF |
36.89 | 147.54 | 79.33 | (89.78) | |
Quick Ratio |
2.54 | 1.23 | 1.20 | 1.08 | |
Current Ratio |
3.29 | 1.70 | 1.87 | 1.72 | |
Net Debt/EBITDA |
(2.14) | (95.76) | 50.54 | 45.02 | |
Debt/Assets |
43.11% | 57.82% | 56.68% | 57.64% | |
Debt/Equity |
(4.79) | (8.98) | (7.13) | (6.28) | |
Asset Turnover |
0.65 | 0.59 | 0.63 | 0.69 | |
Operating CF/Net income |
2.96 | 0.50 | 0.32 | 0.97 | |
Capex/Depreciation |
(0.38) | (0.42) | (0.26) | (0.70) | |
Interest Coverage |
2.58 | (0.55) | (0.13) | (0.02) | |
Research and Development Expense of Revenue |
17.12% | 24.64% | 19.11% | 16.46% | |
Selling, General and Administrative Expense of Revenue |
35.42% | 52.17% | 59.98% | 53.31% | |
Intangible Assets out of Total Assets |
0.01 | 0.09 | 0.10 | 0.10 | |
Share Based Compensation of Revenue |
(6.25%) | 14.67% | 7.16% | 9.35% | |
Graham Net Nets |
(0.11) | (0.32) | (0.73) | (0.42) | |
Graham Number |
0.00 | 0.00 | 0.54 | 0.80 | |
Earnings Yield |
1.90% | 0.39% | (2.77%) | (3.05%) | |
Free Cash Flow Yield |
2.63% | 0.79% | 1.74% | (1.38%) | |
Revenue per Share |
0.27 | 0.37 | 0.29 | 0.35 | |
Operating CF per Share |
0.08 | (0.03) | (0.02) | (0.06) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
0.07 | (0.03) | (0.02) | (0.08) | |
Cash per Share |
0.85 | 0.56 | 0.43 | 0.36 | |
Shareholders Equity per Share |
(0.15) | (0.17) | (0.19) | (0.22) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.15) | (0.17) | (0.19) | (0.22) | |
Free Cash Flow |
22.52 | (9.95) | (7.24) | (23.45) | |
Working Capital |
249.71 | 120.55 | 116.60 | 102.81 | |
Capital Expenditures |
(1.12) | (1.99) | (1.88) | (5.08) | |
Net Current Asset Value |
(180.35) | (551.62) | (552.44) | (553.79) | |
EV/EBIT |
21.93 | 52.05 | 70.30 | 177.12 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.05 | |
Price to Operating Income |
22.57 | 44.66 | 50.89 | 143.29 | |
| Other line items | |||||
Average Receivables |
17.78 | 25.09 | 28.52 | 35.17 | |
Average Payables |
6.86 | 7.91 | 10.59 | 10.65 | |
Average Inventory |
26.82 | 31.60 | 39.03 | 36.46 | |
Average Assets |
479.42 | 593.01 | 577.27 | 572.00 | |
Average Common Equity |
(127.24) | (64.92) | (58.91) | (61.12) |
Columns are period end dates